Oncology News

ESMO oncology news ensures that you're always kept up to date with the latest developments that affect you and your daily practice. Make sure you check these pages frequently, or sign up to our newsletter.

Filter

Date Title Topic
18 Nov 2019 EMA Recommends Extension of Indications for Trastuzumab Emtansine Breast cancer - Anticancer agents & Biologic therapy
15 Nov 2019 Secondary Surgical Cytoreduction Followed by Chemotherapy vs Chemotherapy in Recurrent Ovarian Cancer Gynaecologic malignancies
14 Nov 2019 Clinical Benefit of Pembrolizumab in Previously Treated Advanced MSI-H/dMMR Non-colorectal Cancers Personalised medicine - Cancer Immunology and Immunotherapy
13 Nov 2019 Divergent HLA Allele Linked to Immunotherapy Efficacy Cancer Immunology and Immunotherapy
12 Nov 2019 FDA Approves Luspatercept-aamt for Anaemia in Patients with Beta Thalassemia Palliative and supportive care
11 Nov 2019 Cancer-Related Cognitive Impairment in Cancer Survivors Palliative and supportive care
08 Nov 2019 Crizotinib in c-MET- or ROS1-positive Non-Small Cell Lung Cancer Lung and other thoracic tumours - Personalised medicine - Anticancer agents & Biologic therapy
06 Nov 2019 Gilteritinib for Relapsed or Refractory FLT3-Mutated AML Haematologic malignancies - Personalised medicine - Anticancer agents & Biologic therapy
06 Nov 2019 Efficacy and Biomarker Analysis of Neoadjuvant Immune Checkpoint Blockade in Urothelial Cancer Genitourinary cancers - Cancer Immunology and Immunotherapy
05 Nov 2019 Pembrolizumab as a Combination or Monotherapy in First-line Treatment for Recurrent or Metastatic HNSCC Head and neck cancers - Cancer Immunology and Immunotherapy - Anticancer agents & Biologic therapy
04 Nov 2019 Discovery of AMG 510, a First in Class Oral KRAS G12C Inhibitor Basic science - Translational research - Anticancer agents & Biologic therapy
31 Oct 2019 EMA Guide on Biosimilars for Healthcare Professionals Available Now in 23 Official EU Languages Bioethics, legal and economic issues
30 Oct 2019 Phase I/II Study Results with Lorlatinib in ROS1-positive Advanced NSCLC Lung and other thoracic tumours - Personalised medicine - Anticancer agents & Biologic therapy
29 Oct 2019 Women Report More Adverse Drug Reactions Than Men Palliative and supportive care
28 Oct 2019 FDA Approves Niraparib for HRD-positive Advanced Ovarian Cancer Gynaecologic malignancies - Personalised medicine - Anticancer agents & Biologic therapy